Nanoplastics represent emerging environmental contaminants that pose significant threats to human health. Current research on nanoplastics predominantly focuses on their environmental impact and ex situ degradation. A critical paradigm shift is needed toward developing strategies for their in vivo elimination and therapy. Addressing this gap, a living therapeutic agent based on Escherichia coli Nissle 1917 (EcN) is engineered in this study for charge-enhanced adsorption and remediation of polyethylene terephthalate nanoplastics (nanoPET) in the gastrointestinal tract. This engineered probiotic, EcNp@PDA-PEI, is designed to express PET hydrolase for direct nanoPET biodegradation and coated by polydopamine-polyethyleneimine (PDA-PEI) for prolonging gut retention. The EcNp@PDA-PEI effectively reduces nanoPET uptake by Caco-2 cells, thereby alleviating cellular inflammation and gut barrier disruption. In a murine model of nanoPET-induced colitis, the EcNp@PDA-PEI robustly restores gut barrier integrity, mitigates inflammation, and recalibrates the dysregulated gut microbiota. This work presents a proof-of-concept demonstration of repurposing a PET-degradation system from environmental remediation toward preliminary biomedical exploration, providing a foundational basis for further investigations into nanoplastics-associated health risks